KNSA — Kiniksa Pharmaceuticals International Share News
0.000.00%
Last trade - 00:00- $6.24bn
- $5.71bn
- $677.56m
Brief: Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results And Provides Corporate Update
Kiniksa Pharmaceuticals Ltd expected to post a loss of 44 cents a share - Earnings Preview
Brief: Kiniksa Pharmaceuticals Ltd Files For Mixed Shelf Of Up To $400 Million - SEC Filing
Brief: Kiniksa Pharmaceuticals Files Prospectus Relates To Proposed Resale Of 28,682,554 Class A Common Shares Offered By Selling Shareholders - SEC Filing
Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in March - Earnings Summary
Brief: Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results, Provides Corporate Update
Kiniksa Pharmaceuticals Ltd expected to post a loss of 41 cents a share - Earnings Preview
Brief: Huadong Medicine's Unit Signs Cooperation Agreement With Kiniksa Pharmaceuticals' Unit
Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in December - Earnings Summary
Brief: Kiniksa Pharmaceuticals Reports Fourth Quarter And Full-Year 2021 Results
Brief: Kiniksa Pharmaceuticals And Huadong Medicine Announce Strategic Collaboration
Kiniksa Pharmaceuticals Ltd expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Akamai Technologies, Metacrine, Vaxcyte
U.S. STOCKS ON THE MOVE-Tencent Music, Baudax Bio, Novavax
U.S. STOCKS ON THE MOVE-LiveOne, Tesla, ADDvantage Technologies
U.S. STOCKS ON THE MOVE-Apple, LiveOne, Tesla
Kiniksa Pharma falls as COVID-19 treatment fails late-stage trial
Brief: Kiniksa Announces Phase 3 Trial Of Mavrilimumab In Covid-19-Related ARDS Did Not Meet Primary Efficacy Endpoint
Brief: Kiniksa Pharma Reports Q3 2021 Financial Results And Recent Portfolio Execution